amlodipine/atorvastatin / Generic mfg. - LARVOL DELTA

A Diagnostic Trap: Refractory Gastritis Mimicking Autoimmune and Eosinophilic Disease Caused by Olmesartan (ACG 2026) - "Medications included olmesartan, amlodipine, atorvastatin, empagliflozin, and cyanocobalamin. F. Post-cessation gastric body with atrophic oxyntic mucosa without evidence of intraepithelial lymphocytosis, mucosal eosinophilia, or intestinal metaplasia."

Cardiovascular • Diabetes • Dyslipidemia • Eosinophilia • Eosinophilic Esophagitis • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus

Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma. (PubMed, Cancer Rep (Hoboken)) - "Repurposed drugs may provide useful candidates for improving TMZ-based therapy in GB. However, most evidence remains preclinical, and further studies are needed to clarify blood-brain barrier penetration, optimal dosing, toxicity, predictive biomarkers, and clinical efficacy. Well-designed prospective clinical trials are required before these combinations can be incorporated into routine GB treatment."

Journal • Review • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • AMPK • EGFR • MGMT • STAT3

Maternal and fetal outcomes of lipid-lowering drug use in pregnancy: A Czech nationwide study. (PubMed, J Clin Lipidol) - "Atorvastatin and rosuvastatin had a relatively low risk of adverse maternal and fetal outcomes, comparable to fibrates. Cholestyramine and the fixed combination of statin and amlodipine were associated with increased risk."

Journal • Dyslipidemia

The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin (clinicaltrials.gov) - P4 | N=252 | Completed | Sponsor: Hyo-Soo Kim | Unknown status ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Atypical Presentation of Balint Syndrome in a Patient with Right-sided Occipital-temporal Infarcts: A Case Report (AAN 2026) - "The patient received intravenous thrombolysis, along with edaravone 30mg twice daily for 14 days for neuroprotection, followed by secondary prevention with dual antiplatelet therapy, atorvastatin, amlodipine, and telmisartan. Recognition of such atypical presentations is crucial for timely diagnosis and targeted rehabilitation. However, their rarity limits treatment evidence, underscoring the need for further research to enhance patient care."

Case report • Clinical • Ataxia • Cardiovascular • CNS Disorders • Hematological Disorders • Ischemic stroke • Movement Disorders • Psychosomatic Disorders

Comparative pharmacokinetics of a candesartan/amlodipine/atorvastatin fixed-dose combination 8 mg/5 mg/10 mg versus separate tablets in healthy subjects: a partial replicated crossover study. (PubMed, Transl Clin Pharmacol) - P1 | "This study suggested that the FDC formulation of candesartan, amlodipine, and atorvastatin showed PK equivalence compared to separate tablets. ClinicalTrials.gov Identifier: NCT04611932."

Journal • PK/PD data • Cardiovascular • Dyslipidemia • Hypertension

INTRAVASCULAR LARGE B-CELL LYMPHOMA DIAGNOSED BY RENAL BIOPSY PRESENTING WITH NEPHROTIC SYNDROME (ISN-WCN 2026) - "His past history included hypertension, dyslipidemia, and chronic obstructive pulmonary disease, treated with amlodipine, atorvastatin, indacaterol, and silodosin...R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated, followed by high-dose methotrexate for CNS prophylaxis...This case emphasizes the importance of considering hematologic malignancy in the differential diagnosis of nephrotic syndrome with unexplained fever, even in the absence of hematologic abnormalities. Early renal biopsy allowed timely R-CHOP chemotherapy and resulted in favorable clinical and renal outcomes."

Biopsy • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • BCL6 • CD20 • IL2 • IRF4 • PTPRC

From ASCOT to Asia: A More Active and Successful Approach in Preventing Cardiovascular Disease. (PubMed, Acta Cardiol Sin) - "Notably, the single-pill combination of amlodipine and atorvastatin has been shown to enhance adherence while providing a synergistic effect in protecting the vascular endothelium and preventing CVD. By aggressively managing both conditions, healthcare providers can significantly reduce the risk of future cardiovascular events across diverse patient populations and ethnicities."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Impact of Yoga and Naturopathy in a Patient with Chronic Idiopathic Axonal Polyneuropathy Associated with Metabolic Syndrome and Rheumatoid Arthritis: A Case Report. (PubMed, Adv Mind Body Med) - "Despite adherence to the prescribed conventional treatment regimen (Metformin, Atorvastatin, Amlodipine, Rabeprazole sodium, Domperidone, Gabapentin, Nortriptyline hydrochloride, and Tramadol), as verified from her medical records, the patient's symptoms did not improve. However, as this is a single case report, the findings cannot be generalized; hence, randomized controlled and pilot studies are recommended to validate the findings. case report, chronic idiopathic axonal polyneuropathy, integrative yoga and naturopathy, metabolic syndrome, rheumatoid arthritis."

Journal • Cardiovascular • Diabetes • Hypertension • Immunology • Inflammatory Arthritis • Metabolic Disorders • Pain • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus

Possible Drug-Radiopharmaceutical Interaction in 99mTc-Sestamibi Parathyroid Imaging. (PubMed, Pharmacy (Basel)) - "After a detailed review of his medication profile, it was postulated that there were potential interactions involving multiple P-glycoprotein (P-gp) substrates with specific emphasis on amlodipine, atorvastatin and telmisartan. It highlights the importance of reviewing medication history prior to nuclear imaging, particularly when using radiotracers affected by P-gp mechanisms. This is crucial for mitigating against false-negative results, thus ensuring accurate diagnosis and appropriate clinical management."

Journal • Endocrine Disorders

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Active, not recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Dec 2026 ➔ Sep 2026

Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension

Predictors of Significant High-Sensitivity C-Reactive Protein Reduction After Use of Rosuvastatin/Amlodipine and Atorvastatin/Amlodipine-Subgroup Analysis in Randomized Controlled Trials. (PubMed, J Clin Med) - P4 | " In patients with ATV, RSV/AML polypill, baseline hsCRP ≥ 2 mg/dL, and baseline RSV 20 mg/AML 5 mg were independent predictors of a significant hsCRP reduction. BMI was not associated with hsCRP reduction (Clinical trial: NCT03951207)."

Journal • Acute Myelogenous Leukemia • Genetic Disorders • Obesity • CRP

Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets (Business Standard) - "Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Amlodipine and Atorvastatin Tablets USP. Amlodipine and Atorvastatin tablets are a combination medication used to treat high blood pressure (hypertension) and high cholesterol (hyperlipidemia)....The companys consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24."

ANDA • Commercial • Hypertension • Mixed Hyperlipidemia

SYNERGISTIC LDL-CHOLESTEROL REDUCTION WITH AMLODIPINE AND ATORVASTATIN COMBINATION: A SYSTEMATIC REVIEW AND META-ANALYSIS - Apurva Popat (ACC 2025) - "The combination of amlodipine and atorvastatin is more effective in reducing LDL-C levels compared to atorvastatin monotherapy in patients with hypertension and hypercholesterolemia, unlike ARBs or BBs combined with statins."

Retrospective data • Review • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Phase III Randomized, Double-Blind, Active-Controlled, Multicenter Study on the Efficacy and Safety of Ezetimibe/Atorvastatin/Amlodipine Combination in Patients With Comorbid Primary Hypercholesterolemia and Essential Hypertension. (PubMed, Clin Ther) - "Triple combination therapy with Eze/Ato + Aml has effectively reduced the LDL-C and SBP independently, compared with either Eze/Ato or Aml therapies over 8 weeks of treatment period. In terms of safety, there were no significant differences among the 3 treatment groups. This research lays the groundwork for the development of a triple fixed-dose combination in the future, which could improve patient convenience and adherence by reducing pill burden. Clinical Research Information Service (CRIS), Republic of Korea: KCT0006283."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

SPONTANEOUS ISOLATED CELIAC ARTERY DISSECTION FOLLOWING COCAINE USE (SCCM 2025) - "Toxicology was positive for cocaine and fentanyl...Initial treatment included Nicardipine, opioids, Heparin, Aspirin, Atorvastatin, and later Plavix. The patient was discharged stable on dual antiplatelet therapy, Atorvastatin, Amlodipine, and Losartan, with vascular surgery follow-up planned...Surgery is considered for complications like rupture or organ ischemia. While traumatic dissections may require urgent intervention, SICAD treatment protocol remains uncertain due to limited clinical data."

Atherosclerosis • Cardiovascular • Hypertension • Pain

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database. (PubMed, Ther Adv Neurol Disord) - "Apixaban had the most reports (1631). Disproportionality analyses revealed that rivastigmine, nicergoline, aducanumab, amlodipine/atorvastatin, and dihydroergometrine had the highest risk, based on reporting odds ratio, proportional reporting ratio, and information component. Only valproate and tramadol among the top 50 drugs included a potential dementia risk in their package inserts. This study identified a list of medications associated with dementia risk, many of which lack dementia warnings on their labels. Increased monitoring is necessary for high-risk individuals, and further research is required to clarify these associations and improve patient safety."

Adverse events • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province. (PubMed, Front Pharmacol) - "The strongest signal found in this study was jaundice caused by the combination of amlodipine and atorvastatin (Ω 0.025:3.08, lift: 1116.69, conviction: 1.75)...Patients under 60 years old had a palpitations signal when combining eritrea bei sha Tanzania and felodipine (Ω 0.025:0.41, lift: 14.65, conviction: 3.8), and an erythema signal when combining nifedipine (Ω 0.025:0.23, lift: 8.17, conviction: 1.077)...Five adverse events associated with aspirin-induced bleeding were identified. Notably, different adverse drug reactions were observed in different populations, suggesting the need for future studies to expedite the development of personalized medicine."

Adverse drug reaction • Journal • Cardiovascular • CNS Disorders • Dermatology • Hematological Disorders • Hepatology • Vascular Neurology

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese with Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Active, not recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension

The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide."

Journal

Real-World Statin Use and 10-Year Atherosclerotic Cardiovascular Disease Risk in Patients With Biopsy-Confirmed Metabolic Dysfunction Associated Steatohepatitis in an Integrated Delivery Network (ACG 2024) - "3,442 MASH patients had data available to calculate ASCVD risk – 1,359 (39.5%) statin users and 2,083 (60.5%) nonusers. Baseline type 2 diabetes, smoker, and hypertension rates were 29.4%, 51.1%, and 97.2% in statin users and 22.6%, 30.8%, and 36.7% in nonusers. Identified statins included atorvastatin (n=756), amlodipine/atorvastatin (n=3), fluvastatin (n=1), lovastatin (n=12), pitavastatin (n=1), pravastatin (n=152), rosuvastatin (n=290), simvastatin (n=136), and simvastatin/ezetimibe (n=2)."

Biopsy • Clinical • Real-world • Real-world evidence • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Heart Failure • Hepatology • Hypertension • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Type 2 Diabetes Mellitus

Dengue Virus-Induced Acute Interstitial Nephritis (KIDNEY WEEK 2024) - "Home medications were Amlodipine, Atorvastatin and Sildenafil...The patient was discharged on Prednisone taper for two weeks...There have been reports of ATN secondary to severe rhabdomyolysis in dengue fever but there has not been any reported case of AIN. Even though amlodipine has been reported to cause interstitial nephritis, the patient had been taking it for more than a year before the presentation, without any worsening of his renal functions.."

Acute Kidney Injury • Cardiovascular • Dengue Fever • Dyslipidemia • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Nephrology • Pain • Renal Disease

Phase 1 Evaluation of the Bioequivalence and Drug-Drug Interaction Potential of a Novel Fixed-Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine. (PubMed, Clin Pharmacol Drug Dev) - "Geometric mean ratios (FDC to individual formulations) and 90% confidence intervals of area under the time-concentration curve at steady state during dosing interval (AUCτ, ss) and maximum concentration at steady state (Cmax, ss) or amlodipine, atorvastatin, and ezetimibe were all within the bioequivalent range (0.8-1.25), confirming bioequivalence. Moreover, the FDC of ezetimibe, atorvastatin, and amlodipine exhibited comparable tolerability to corresponding individual formulations."

Journal • P1 data • Cardiovascular

Transmural changes of microscopic colitis using intestinal ultrasound: a case report (AGW-GESA 2024) - "Her past medical history included high cholesterol, hypertension and anxiety, for which she was prescribed longstanding atorvastatin, amlodipine and venlafaxine...The patient was commenced on intravenous hydrocortisone 100mg QID with excellent clinical (bowel frequency reduced to 2) and biochemical response over a 48-hour period and was transitioned to prednisolone and later budesonide... Beyond diagnosis, this case further demonstrates the potential for GIUS to monitor response to treatment of collagenous colitis. We would advocate for the routine use of GIUS in the evaluation of patients with chronic diarrhoeal illnesses given its non-invasive nature and utility in serial evaluation."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Nephrology • Psychiatry • Renal Disease • CRP

STOP-PA: Statin Combined With Amlodipine Treats Primary Aldosteronism (clinicaltrials.gov) - P4 | N=150 | Not yet recruiting | Sponsor: Third Military Medical University

New P4 trial • Cardiovascular • Endocrine Disorders • Hypertension